CL2014001546A1 - Compuestos derivados de triazolopiridina, como inhibidores de ttk; metodo de preparacion de dichos compuestos; composicion y combinacion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis, tumores gastrointestinales, del tracto urinario, tumores mamarios y otros tumores ginecologicos, entre otros. - Google Patents

Compuestos derivados de triazolopiridina, como inhibidores de ttk; metodo de preparacion de dichos compuestos; composicion y combinacion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis, tumores gastrointestinales, del tracto urinario, tumores mamarios y otros tumores ginecologicos, entre otros.

Info

Publication number
CL2014001546A1
CL2014001546A1 CL2014001546A CL2014001546A CL2014001546A1 CL 2014001546 A1 CL2014001546 A1 CL 2014001546A1 CL 2014001546 A CL2014001546 A CL 2014001546A CL 2014001546 A CL2014001546 A CL 2014001546A CL 2014001546 A1 CL2014001546 A1 CL 2014001546A1
Authority
CL
Chile
Prior art keywords
tumors
compounds
triazolopyridine
metastases
prophylaxis
Prior art date
Application number
CL2014001546A
Other languages
English (en)
Inventor
Volker Schulze
Antje Margret Wengner
Gerhard Siemeister
Detlef Stöckigt
Michael Bruening
Dirk Kosemund
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of CL2014001546A1 publication Critical patent/CL2014001546A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2014001546A 2011-12-12 2014-06-12 Compuestos derivados de triazolopiridina, como inhibidores de ttk; metodo de preparacion de dichos compuestos; composicion y combinacion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis, tumores gastrointestinales, del tracto urinario, tumores mamarios y otros tumores ginecologicos, entre otros. CL2014001546A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11193011 2011-12-12

Publications (1)

Publication Number Publication Date
CL2014001546A1 true CL2014001546A1 (es) 2014-10-24

Family

ID=47427291

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001546A CL2014001546A1 (es) 2011-12-12 2014-06-12 Compuestos derivados de triazolopiridina, como inhibidores de ttk; metodo de preparacion de dichos compuestos; composicion y combinacion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis, tumores gastrointestinales, del tracto urinario, tumores mamarios y otros tumores ginecologicos, entre otros.

Country Status (39)

Country Link
US (1) US9663510B2 (es)
EP (1) EP2791136B1 (es)
JP (1) JP6181664B2 (es)
KR (1) KR20140105552A (es)
CN (1) CN104114552B (es)
AP (1) AP4017A (es)
AR (1) AR089143A1 (es)
AU (1) AU2012350751B2 (es)
BR (1) BR112014014184A2 (es)
CA (1) CA2858683A1 (es)
CL (1) CL2014001546A1 (es)
CO (1) CO6980657A2 (es)
CR (1) CR20140275A (es)
CU (1) CU20140068A7 (es)
CY (1) CY1116958T1 (es)
DK (1) DK2791136T3 (es)
DO (1) DOP2014000133A (es)
EC (1) ECSP14004812A (es)
ES (1) ES2550677T3 (es)
GT (1) GT201400111A (es)
HR (1) HRP20151103T1 (es)
HU (1) HUE025937T2 (es)
IL (1) IL232930A (es)
JO (1) JO3111B1 (es)
MA (1) MA35826B1 (es)
MX (1) MX2014007057A (es)
PE (1) PE20141597A1 (es)
PH (1) PH12014501319A1 (es)
PL (1) PL2791136T3 (es)
PT (1) PT2791136E (es)
RS (1) RS54288B1 (es)
RU (1) RU2632464C1 (es)
SG (1) SG11201402820SA (es)
SI (1) SI2791136T1 (es)
TN (1) TN2014000254A1 (es)
UA (1) UA112096C2 (es)
UY (1) UY34515A (es)
WO (1) WO2013087579A1 (es)
ZA (1) ZA201404031B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2878481A1 (en) * 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
RS56034B1 (sr) * 2013-06-11 2017-09-29 Bayer Pharma AG Derivati prolekova supstituisanih triazolopiridina
HK1219879A1 (zh) 2013-06-11 2017-04-21 Bayer Pharma Aktiengesellschaft 用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
CN106414447A (zh) * 2014-05-19 2017-02-15 Udc 爱尔兰有限责任公司 具高效率的荧光有机发光元件
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
CN107635586B (zh) 2014-12-15 2021-09-24 拜耳医药股份有限公司 Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc)
CN105985241A (zh) * 2015-01-27 2016-10-05 邵阳学院 α-取代苯乙酸酯类化合物α-糖苷酶抑制作用及其应用
RU2751512C2 (ru) 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
WO2016207094A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CN114921391B (zh) * 2016-10-27 2024-01-02 拜耳股份有限公司 4,5-环状1,2,4-三唑酮
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
CN106831555B (zh) * 2017-01-22 2019-09-24 中国农业大学 吡啶酰胺类化合物及其制备方法与应用
KR102668688B1 (ko) 2018-07-23 2024-05-24 삼성디스플레이 주식회사 유기 발광 소자
CA3128946A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
KR102661468B1 (ko) 2019-02-15 2024-04-30 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 전자 장치
KR102897919B1 (ko) 2019-11-14 2025-12-09 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 장치
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010005700A (es) 2007-11-27 2010-06-11 Cellzome Ltd Amino triazoles como inhibidores pi3k.
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
SG173610A1 (en) 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
BR112012017310A2 (pt) 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
JP2011246389A (ja) * 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
HRP20150517T1 (hr) * 2011-04-21 2015-06-19 Bayer Intellectual Property Gmbh Triazolopiridini

Also Published As

Publication number Publication date
JP6181664B2 (ja) 2017-08-16
MA35826B1 (fr) 2014-12-01
UA112096C2 (uk) 2016-07-25
UY34515A (es) 2013-07-31
MX2014007057A (es) 2014-08-08
JO3111B1 (ar) 2017-09-20
DK2791136T3 (en) 2015-10-26
HK1203200A1 (en) 2015-10-23
RU2632464C1 (ru) 2017-10-05
SG11201402820SA (en) 2014-06-27
GT201400111A (es) 2015-11-30
BR112014014184A2 (pt) 2017-06-13
PT2791136E (pt) 2015-11-04
CU20140068A7 (es) 2014-12-26
DOP2014000133A (es) 2014-07-31
HUE025937T2 (en) 2016-05-30
AU2012350751B2 (en) 2017-07-06
RS54288B1 (sr) 2016-02-29
US9663510B2 (en) 2017-05-30
PH12014501319A1 (en) 2014-09-08
WO2013087579A1 (en) 2013-06-20
AR089143A1 (es) 2014-07-30
CA2858683A1 (en) 2013-06-20
TN2014000254A1 (en) 2015-09-30
CN104114552B (zh) 2016-12-28
PE20141597A1 (es) 2014-11-07
ZA201404031B (en) 2016-09-28
PL2791136T3 (pl) 2015-12-31
SI2791136T1 (sl) 2015-11-30
CR20140275A (es) 2014-08-13
US20150210683A1 (en) 2015-07-30
ECSP14004812A (es) 2015-11-30
CY1116958T1 (el) 2017-04-05
HRP20151103T1 (xx) 2015-11-20
KR20140105552A (ko) 2014-09-01
EP2791136B1 (en) 2015-07-29
IL232930A (en) 2016-07-31
CO6980657A2 (es) 2014-06-27
AU2012350751A1 (en) 2014-06-26
AP4017A (en) 2017-01-28
CN104114552A (zh) 2014-10-22
NZ625815A (en) 2016-07-29
ES2550677T3 (es) 2015-11-11
EP2791136A1 (en) 2014-10-22
IL232930A0 (en) 2014-08-03
AP2014007731A0 (en) 2014-06-30
JP2015500308A (ja) 2015-01-05

Similar Documents

Publication Publication Date Title
CL2014001546A1 (es) Compuestos derivados de triazolopiridina, como inhibidores de ttk; metodo de preparacion de dichos compuestos; composicion y combinacion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis, tumores gastrointestinales, del tracto urinario, tumores mamarios y otros tumores ginecologicos, entre otros.
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
UY34649A (es) Compuestos heterobicíclicos
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2015003491A1 (es) Compuestos químicos.
CL2015002628A1 (es) Compuestos de heteroarilo y sus usos.
CL2014001062A1 (es) Metodo para tratar tumores del estroma gastrointestinal que comprende el uso de un inhibidor de c-hit y un inhibidor de pi3k o fgfr y combinacion que comprende a los compuestos.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2015002194A1 (es) Inhbidores de erk y sus usos
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
CL2014001065A1 (es) Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer.
PT2753334T (pt) Inibidores de proteassoma ativados por fap utilizados para o tratamento de tumores sólidos
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
LT3190113T (lt) Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
BR112014030155A2 (pt) tratamento de harq-ack para subquadros de downlink não intencionais.
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CL2012001422A1 (es) Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
BR112014031263A2 (pt) composto, composição farmacêutica, métodos para inibir a secreção wnt e para inibir sinalização wnt, uso do composto ou sal e método para tratar um distúrbio.
CL2015002591A1 (es) Entidades químicas.